My focus is on the pathology and natural history of prostate, testicular and penile cancer working to translate basic research into practical treatments for patients with novel tests and bespoke predictive treatments.
My research focuses on molecular pathology of pancreatic cancer, in particular its development and progression. We are using this knowledge to develop biomarkers for early, non-invasive detection of this malignancy in urine specimens.
We aim to identify genetic alterations that influence cancer development, progression and therapeutic responses, in particular prostate cancer, and further develop them into biomarkers for cancer diagnosis and therapeutic stratification, with a current focus on circulating biomarkers.
I have broad research interests and experience in bioinformatics, cancer genomics and data analytics. These research areas mainly involve developing and applying bioinformatics and computational approaches to analyse large-scale cancer datasets to uncover novel diagnostic and prognostic biomarkers. I also lead the Cancer Research UK Barts Centre Bioinformatics Core Facility.
I am providing bioinformatics support for several projects focusing on squamous cell carcinoma. This generally involves developing bioinformatics pipelines for large-scale cancer datasets and utilising computational approaches for analysis, with the overall aim being to uncover novel diagnostic and prognostic biomarkers.
My research focuses on measuring circulating tumour cells as a blood-based biomarker for aggressive prostate cancer.
My research interest focuses on risk stratification signatures for Barrett’s oesophagus progression to cancer using high throughput multiplexed imaging, bioinformatics, shallow whole genome sequencing, and spatial transcriptomics.
My research is focused on cancer immunotherapy for pancreatic cancer, particularly immune-stimulatory molecules, armed oncolytic viruses and CAR T-cells.